ID   MM-S1
AC   CVCL_M538
SY   MM_S1; MM.S1
DR   cancercelllines; CVCL_M538
DR   Cosmic; 720781
DR   Cosmic; 2367271
DR   Wikidata; Q54906025
RX   DOI=10.1007/0-306-46877-8_4;
RX   PubMed=1720489;
RX   PubMed=2072743;
RX   PubMed=2167671;
RX   PubMed=10936422;
RX   PubMed=11157491;
RX   PubMed=18647998;
CC   Population: Japanese.
CC   Characteristics: Produces Ig lambda.
CC   Characteristics: IL6 dependent.
CC   Doubling time: 24 hours (PubMed=2072743).
CC   Sequence variation: Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Unspecified (PubMed=11157491).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
CC   Cell type: B-cell; CL=CL_0000236.
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   56Y
CA   Cancer cell line
DT   Created: 05-11-13; Last updated: 19-12-24; Version: 18
//
RX   DOI=10.1007/0-306-46877-8_4;
RA   Jernberg-Wiklund H., Nilsson K.;
RT   "Multiple myeloma cell lines.";
RL   (In book chapter) Human cell culture. Vol. 3. Cancer cell lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York; USA (2000).
//
RX   PubMed=1720489; DOI=10.1016/0145-2126(91)90110-f;
RA   Suzuki A., Takahashi T., Okuno Y., Fukumoto M., Fukui H.,
RA   Koishihara Y., Ohsugi Y., Ohno Y., Imura H.;
RT   "Estimation of interleukin 6 production by reverse
RT   transcriptase-polymerase chain reaction in four human myeloma cell
RT   lines.";
RL   Leuk. Res. 15:1043-1050(1991).
//
RX   PubMed=2072743;
RA   Okuno Y., Takahashi T., Suzuki A., Ichiba S., Nakamura K.,
RA   Fukumoto M., Okada T., Okada H., Imura H.;
RT   "Establishment and characterization of four myeloma cell lines which
RT   are responsive to interleukin-6 for their growth.";
RL   Leukemia 5:585-591(1991).
//
RX   PubMed=2167671; DOI=10.1016/0006-291x(90)90510-t;
RA   Okuno Y., Takahashi T., Suzuki A., Ichiba S., Nakamura K., Hitomi K.,
RA   Sasaki R., Imura H.;
RT   "Expression of the erythropoietin receptor on a human myeloma cell
RT   line.";
RL   Biochem. Biophys. Res. Commun. 170:1128-1134(1990).
//
RX   PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2;
RA   Drexler H.G., Matsuo Y.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   multiple myeloma and plasma cell leukemia.";
RL   Leuk. Res. 24:681-703(2000).
//
RX   PubMed=11157491; DOI=10.1182/blood.V97.3.729;
RA   Chesi M., Brents L.A., Ely S.A., Bais C., Robbiani D.F., Mesri E.A.,
RA   Kuehl W.M., Bergsagel P.L.;
RT   "Activated fibroblast growth factor receptor 3 is an oncogene that
RT   contributes to tumor progression in multiple myeloma.";
RL   Blood 97:729-736(2001).
//
RX   PubMed=18647998; DOI=10.1093/jncimonographs/lgn011; PMCID=PMC2737184;
RA   Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M.;
RT   "Characterization of MYC translocations in multiple myeloma cell
RT   lines.";
RL   J. Natl. Cancer Inst. Monogr. 39:25-31(2008).
//